Клиническое значение контроля за системой гемостаза в процессе ведения больных опухолями яичников
Диссертация
Перед оперативным вмешательством у больных опухолями яичников наряду с выявлением скрытых маркеров тромбофилии, необходимо проведение общеоценочных тестов (АЧТВ, АВР, уровень фибриногена, количество тромбоцитов) для выявления коагулопатии потребления и заместительной терапии свежезамороженной плазмой с целью профилактики интраи послеопе-рацонных геморрагических осложнений. Кроме того, проведено… Читать ещё >
Содержание
- Введение. стр
- Глава I. Нарушения гемостаза и тромбогеморрагические осложнения у больных опухолями яичников (обзор литературы). стр
- Глава II. Общеклиническая характеристика больных. Материалы и методы исследования. стр
- 2. 1. Клиническая характеристика обследованных пациенток
- 2. 2. Методы исследования. стр
- Глава III. Сравнительная оценка изменений в системе гемостаза при доброкачественных и злокачественных опухолях яичников. стр
- Глава IV. Клинико-гемостазиологические особенности больных раком яичников, получавших химиотерапию. стр
Список литературы
- Артамонов B.C., Глущенко И. В. //Клиническое значение определения продуктов распада фибриноген/фибрин у больных опухолями яичников.// Клинические аспекты внутрисосудистого свертывания крови. Киев, 1982.-192−196.
- Балуда В.П. с соавт. Профилактика тромбозов. Саратов, 1992.
- Баркаган З.С. //Клинико-патогенетические варианты, номенклатура и основы диагностики гематогенных тромбофилий.// Пр. гем. и пер. кр. 1996, № 3, 515.
- Баркаган З.С. Геморрагические заболевания и тромбозы. М. Медицина, 1988 528с.
- Баркаган З.С. //Патогенез и терапия нарушений гемостаза у онкологических больных.// Тер. Архив 1997, № 7, 65−67.
- Бохман Я.В. Руководство по онкогинекологии. М.: Медицина, 1989.
- Бохман Я.В., Лившиц М. А., Винокуров В. Л., Чкуасели Г. Т., Максимов С. Я., Вишневский A.C., Рыбин Е. П., Урманчеева А. Ф. Новые подходы к лечению гинекологического рака. Санкт-Петербург: Гиппократ, 1993.
- Вишневская Е.Е., Бохман Я. В. Ошибки в онкогинекологической практике. -Минск, Вышэйшая школа, 1994.
- Воробьев П.А. Синдромы диссеминированного внутрисосудистого свертывания крови. М. Нью-диамед-АО, 1994−32 с.
- Ю.Голобородько О. П., Веремеенко К. Н. //Активаторы плазминогена в клетках злокачественных опухолей.// Эксперим. онкология, 1982, том 4, № 1, 3−7.
- И.Горбунова В. А. //Лекарственное лечение рака яичников: стандарты и перспективы.// Consilium-medicum, том 3, 2001, № 1.
- З.Грачева Л. //Мукоцеллюлярная карцинома яичников и овариальные метастазы рака молочной железы.// РМЖ, 1998, том 6, № 1.
- Данилова А.Б. с соавт.//Нарушения системы свертывания крови у онкологических больных.// Вопросы онкологии, 1998 г, 44, № 1, 12−18.
- Жуковская Е.С. //Влияние противоопухолевых препаратов на систему гемостаза онкобольных.// Вопросы онкологии, 1980, том 26, № 9, 22−27.
- Капацинский Е.В. //Профилактика тромбоэмболических осложнений у онкологических больных.// Сов. медицина, 1983, № 4, 69−72.
- Кулинич С.И., Шипкова Л. Ш., Черняк Е. В., Логунов В. А., Харченко Н. П. //Опухоли яичников: эпидемиология, диагностика, лечение.// Consilinm-medicum, том 1, 1999, № 3.
- Лычев В.Г. Диагностика и лечение ДВС крови.-М., Медицина, 1993 155.
- Маджуга A.B., Соловьева Е.А." Сомонова О. В., Елизарова А. Л. Диагностика операционных коагулопатических кровотечений у онкологических боль-ных.//Вопр онкол 1990, № 4, 85−89.
- Маджуга А. В., Сомонова О. В., Елизарова А. Л., Астахова В. М., Кормош Ы. Г. //Состояние системы гемостаза у больных раком яичников// Клиническая лабораторная диагностика 2000, № 10, 43−49.
- Макацария А.Д., Мищенко АЛ. //Диагностика претромботических состояний в клинической практике.// Сов. мед. 1982, № 6, 56−60.
- Малежик Л.П., Альфонсов В. В. //К патогенезу нарушений гемостаза при злокачественных новообразованиях.// Вопр. онкологии 1984, том 30, № 4, 4347.
- Павловский Д.П. //Тромбогеморрагический синдром у онкологических больных.//Клин. мед. 1981, том 59, № 5, 16−20.
- Поддубная И.В. //Лекарственная терапия злокачественных опухолей (современное состояние и перспективы).// РМЖ, 1998, тем 6, № 10.
- Российский консенсус. Профилактика послеоперационных венозных тром-боэмболических осложнений. Consilium-Medicum 2000, т. 2, № 4
- Савельев ВМ. Профилактика послеоперационных тромбоэмболических осложнений. Consilium-Medicum 2000-т.2-№ 4.
- Селезнева Н.Д., Стрижаков А. Н., Макацария А. Д., Савченко В. Ф. ПО применении малых доз гепарина для профилактики послеоперационных тромбо-гических осложнений у гинекологических больных.// Акуш. и гинек., 1982, № 1 1, 27−29.
- Серов В.П., Макацария А. Д. Тромбогические и геморрагические осложнения в акушерстве. М., 1987.
- Тамарин И.В. Мононуклеарные фагоциты, сиситема гемостаза и синдром внутрисосудистого свертывания крови.//Тер арх 1986, № 9, 130−137.
- Терещенко И.П., Кашулина А. П. Патофизиологические аспекты злокачественного роста. М., Медицина, 1983 — 239.
- Трапезников H.H., Аксель Е. М., Бармина Н. М. //Заболеваемость и смертность от злокачественных новообразований населения России в 1996 г.// РМЖ, 1998, том 6, № 10.
- Тюляндин A.C. Рак яичников. Москва, 1996.
- Ферстаге М., Фермилен Ж. Тромбозы. Пер. с англ. М., Медицина, 1986 -328.
- Харитонова Т.В. //Опухоли яичников: клинические проблемы.// РМЖ, 1998, том 6, № 10.
- Adamson L.V., Hanf V., Mittman S.G. et al. Release of Anti-PAF-Binding Human Ovarian Cnacer Cells in Culture. Anticancer research 12:293−296 (1992).
- Agnelli G. Venous thromboembolism and cancer: A two-way clinical assosiation. Thromb Haemost 1997- 78: 117−120
- Amengual O., Atsumi Т., Khamashata MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998 Feb-79(2):276−281.
- Asakura H., Kamikubo Y., Goto A., et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res 1995−80:217−224.
- Baron J A, Gridley G, Weiderpass E. Venous thromboembolism and cancer. Lancet 1998−351:1077−1080.
- Bastida E. The metastatic cascade: potential approaches for the inhibition of metastasis. Semin Thromb Hemost 1988−14:66−72.
- Bayer WI, Bodensteiner DC, Tilzer LL, et al. Use of platelets and other transfusion products in patients with malignancy. Semin Thromb Hemost 1992−18:380−391.
- Bell WR, Starksen NF, Tong S, Porterfield JK. Trousseau’s syndrome. Devastating coagulopathy in the absence of heparin. Am J Med 1985 0ct-79(4):423−30.
- Bell WR. The fibrinolytic system in neoplasia. Semin Thromb Hemost 1996−22(6):459−78.
- Bertomeu MC, Gallo S, Lauri D. Chemotherapy enhances endothelial reactivity to platelets. Clin Expl Metastasis 1990−8:511−518
- Bick RL. Clinical implications of molecular markers in hemostasis and thrombosis. Semin Thromb Hemost 1984−10:290−293.
- Bick RL, Baker WF. Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost 1994−20(1):3-l 5.
- Bick RL. Coagulation abnormalities in malignancy: A review. Semin Thromb Hemost 18:353−372,1992
- Bick RL. Disseminated intravascular coagulation: objective criteria for diagnosis and management. Med Clin North Am 1994−78:511.
- Boehme MW, Deng Y, Raeth U, et al. Release of thrombomodulin from endothelial cells by concerted actions of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 1996−87:134−140.
- Bolan CD, Alving BM. Recurrent venous thrombosis and hypercoagulable states. Am Fam Physician 1991 -44(5): 1741 -1751.
- Bona RD, Sivjee KY, Wallace DM. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995−74:1055−1058.
- Boneu B, Bugat R, Eche N, Sie P. Exhausted platelets in patients with malignant solid tumors without evidence of active consumption coagulopathy. Eur J Cancer Clin Oncol 1984−20:899−903.
- Brighton TA, Chesterman NC. Antophospholipid antibodies and thrombosis. Baillieres Clin Haematol 1994−7(3):541−557.
- Cabre F, Tost D, Suesa N et al. Synthesis and release of platelet activation factor and eicosanoids in human endothelial calls induced by different agonists. Agents and Actions 1993−38:212−219.
- Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992−70:1194−1201.
- Camerer E, Kolsto AB, et al. Cell biology of tissue factor: the principal initiator of blood coagulation. Thromb Res 1996−81:1−41.
- Canney PA, Wilkinson PM. Pulmonary embolism in patients receiving chemotherapy for advanced ovarian cancer. Eur J Cancer Clin Oncol 1985−21:585.
- Canobbio L, Fassio T, et al. Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients. Cancer 1986−58:1032−1036.
- Caslen B, Bossmar T, Lccander I, Astedt B. Plasminogen activators and plasminogen activator inhibitors in blood and tumor fluids of patients with ovarian cancer. Eur J Cancer 1994−30A (9): 1302−9.
- Cavanaugh P, Sloane B, Honn K. Role of the coagulation system in tumor-cell induced platelet aggregation and metastasis. Haemostasis 1998−18:37−46.
- Clagget GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988−208:227−240.
- Clarke-Pearson DL. Prevention of venous thromboembolism in gynecological surgery patients. Curr Opin Obstet Gynecol 1993 Feb-5(l):73−9.
- Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecological oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983 Mar I- 145(5):606−13.
- Collen A, Smorenburg SM, Peters E, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Canccr Res 2000 Nov !-60(21):6196−200.
- Colucci M, Balconi G, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983−71:1893−1896
- Constantini V, Zacharski LR, et al. Occurrence of compounds of fibrinolysis pathways in situ in neoplastic and nonneoplastic breast tissue. Cancer Res 1991 -1:354
- Constantini V, Zacharski LR. Fibrin and cancer. Thromb Haemost 1993−69:406.
- Constantini V, De Monte P, Cazzato AO, et al. Systemic thrombin generation in cancer is correlated with extrinsic pathway activation. Blood Coagul Fibrinolysis 1998−9:79−84.
- De Jaco P, Asselain B, Orlandi C. Evaluation of circulating tumor necrosis factor-alpha in patients with gynecological malignancies. Int J Cancer 1991 -48:375−378.
- Den Ouden M, Ubachs JMH, Stoot JEGM, et al. Thrombin-antithrombin III and D-dimer plasma levels in patients with benign or malignant ovarian tumors. Scand J Clin Lab Invest 1998−58:555.
- Derksen RH, de Groot PG, Kater L, Nieuwenhuis HK. //Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulant treatment.//Ann Rheum Dis 1993−52(9):686−692.
- Desroys du Roure F, Louvet C, de Grammont A, et al. //Detectiion of ovarian adenocarcinoma in the occasion of cerebrovascular complication associated with consumption coagulopathy.//Rev Med Interne 1994−15(1):48−51.
- Donati MB. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995 Jul-74(l):278−81.
- Dvorak HF. Thrombosis and cancer// Hum Pathol 1987−18:275−284.
- Edwards RL, Rickles FR. Haemostatic alteration in cancer patients.// Hemostatic Mechanisms and Metastasis. Boston, 1984:384.
- Edwards RL, Rickles FR, Moritz TE. Abnormalities of blood coagulation in patients with cancer. Am J Clin Pathol 1987−88:596−602.
- Edwards RL, Klaus M, Mathews E. Heparin abolishes the chemotherapy induced increase in plasma fibrinopeptid A levels. Am J Med 1990−89:25.
- Edwards RL, Silver J, Rickles FR. Human tumor procoagulants: registry of the subcommittee on haemostasis and malignancy, etc. Thromb Haemost 1993−69:205−213.
- El Bouhmacli A, LalTargue F, Brun JF. Aggregability and disagregability of erythrocytes in women suffering from ovarian cancer: evidence for an increased disaggregation threshold. Clin Hemorheol Microcirc 2000−22(2):91−7.
- Falanga A, Rickles FR, Barburi T, et al. Guidelines for clotting studies in cancer patients. Thromb Haemost 1993−70:540.
- Falanga A, Ofosu FA, Cortelazzo S, et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993−85:745−750.
- Falanga A, Ofosu FA, Delaini F, et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibition. Blood Coagul Fibrinolysis Suppl 1994- 1: S 19−23.
- Falanga A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Flaemostasis 1998−28 Suppl 3:50−60.
- Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Heam 1999−25:173−182.
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995−1:27−31.
- Folkman J. Tumor angiogenesis and tissue factor. Nat Med 1996−2:167−168.
- Francis JL. Flaemostasis and Cancer. Med Lab Sci 1989−46:331−346.
- Frost P, Hart 1, Kerbel R. The hemostatic system in malignancy. Cancer Metastasis Rev 1992- 11:223−234.
- Gallus AS, Hirsh J. Prevention of venous thrombosis with small subcutaneous doses of heparin. JAMA 1976−235:1980−1982.
- Gaducci A, Biacchi U, Marrai R, et al. Pretreatment plasma levels of fibrinopeptide-1 (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol Oncol 1994−53:352.
- Gaducci A, Biacchi U, Marrai R, et al. Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer. Gynecol Oncol 1997−66:85.
- Gerdin B, Saldeen T. Effect of fibrin degradation products on microvascular permeability. Thromb Res 1995- 13:995.
- Girolami A. Low molecular weight heparins in clinical practice: unsolved or partially solved problems. Arch Inst Cardiol Mex 1998 Jan-Feb-68(l):69−76.
- Goad KE, Gralnick HR. Coagulation disorders in cancer. Hematol Oncol Clin North Am 1996−10:457−484.
- Goodnough LT, Saito H, et al. Increased incidence of thromboembolism in stage IV breast cancer patients treated with five drugs chemotherapy regimen. Cancer 1984−54:1264.
- Gordon SG. Cancer cell procoagulants and their role in malignant disease. Semin Thromb Hemost 1992−18:424−433.
- Gorelik E. Protective effect of fibrin on tumor metastases. Fibrinolysis 1992- 6 (Suppl 1):35−38.
- Gouin-Thibault I, Samama MM. Laboratory diagnosis of the thrombophilic state in cancer patients. Semin Thromb Haem 1999−25:167−172.
- Greczy CL. Cellular mechanisms for the activation of blood coagulation. Int Rev Cytol 1994- 152:49.
- Green KB, Siverstein RL. Hypercoagulability in cancer. Hematol Oncol Clin North Am 1996−10:499−530.
- Green D, Maliekel K, Sushko E. Activated protein C resistance in cancer patients. Haemostasis 1997−27:112−118.
- Graf AH, Traun H, Staudach A. Risk and prevention of thromboembolism complications in gynecologic malignancies. Gynacol Geburt Rund 1996−36(1):37−9.
- Gralnick HR. Von Willcbrand factor, integrins and platelets: their role in cancer. J Lab Clin Med 1992- 119:444−447.
- Gringani G, Jameson GA. Platelets in tumor metastasis. Blood 1988−71:844−849.
- Haas S. Limitaions of established antithrombotic strategies. Blood Coagul Fibrinolysis 1999 Aug- 10 Suppl 2: S11−8.
- Haas S. Low molecular weight heparins in the prevention of venous thromboembolism in nonsurgical patients. Semin Thromb Hemost 1999- 25 Suppl 3:101−5.
- Hajar KA. Cellular receptors in the regulation of plasmin generation. Thromb Haemost 1995−74:294.
- Harlap S. The epidemiology of ovarian cancer. In: Markam M, Hoskins WJ, eds. Cancer of the ovary. New York: Raven Press Ltd, 1993:79.
- Hart DA. Dysregulation of plasminogen activators in cancer potential role in invasion metastasis and as a prognostic factor. Fibrinolysis 1992- 6 (Suppl 1):11−15.
- Heilmann L, von Tempelhoff GF, Schneider DM. Prevention of thrombosis in gynecological malignancy. Clin Appl Thromb Hemost 1998−4:153.
- Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Cancer Inst 1999 Jan 6−91(l):22−36.
- Hettiarachchi RJ, Prins MFI. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism. Curr Opin Pulm Med 1998−4:220−225.
- Hiramoto R, Bernecky J, Pressman D. Fibrin in human tumors. Cancer Res 1998−20:592.
- Honn KV, Bookman RS, Marnet LS. Prostaglandins and cancer. A review of tumor initiation through tumor metastasis. Prostaglandins 1981−21:833−864.
- Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenona. Semin Thromb Hemost 1992- 18:392−415.
- Hull RD, Pineo GF. Treatment of venous thromboembolism with low-molecular-weight heparin. J Thromb Thrombolysis 1995-l (3):279−284.
- Ishibashi M, Ito N, Fujita M, et al. Endothelin I as an aggravating factor of disseminated intravascular coagulation associated with malignant neoplasms. Cancer 1994−73:191−195.
- Iversen N, Lindahl AK. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998−102:889−895.
- Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer patients. Semin Thromb Haem 1999−25:239−243.
- Karpatkin S, Nierodzik ML, Klepfish A. Role of platelets and thrombin in cancer. Vessels 1996−2:17−23.
- Khan MM, Puniyani RR, Huilol NG. Hemorheological profiles in cancer patients. Clin Hemorheol 1995−15:37−44.
- Khoo SK, Rylatt DB, Parsons P. Serial D-dimer levels in the assessment of tumor mass and clinical outcome in ovarian cancer. Gynecol Oncol 1988−29:188−198.
- Korte W. Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future and therapeutic procedures. Clin Chem Lab Med 2000 Aug-38(8):679−92.
- Kwaan HC, Keet HN. Fibrinolysis and cancer. Semin Thromb Haemost 1990−16:230−235.
- Lane DA, Adams L. Non-anticoagulant uses of heparin. N Engl J Med 1993−329:129−130.
- Lee AY, Lcvine MN. The thrombophilia state induced by therapeutic agents in the cancer patients. Semin Thromb Flemost 1999−25(2): 137−45.
- Letai A, Kilter DJ. Cancer, coagulation and anticoagulation. Oncologist 1999−4:443−449.
- Levine MN, Raskob GE, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995−108:276−290.
- Lcvine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 1997:78(1): 133−36.
- Levine MN. Treatment of thrombotic disorders in cancer patients. Haemostais 1997−27 Suppl 1:38−43.
- Levy PJ, Gonzzalez FM, Rush DS, Haynes JL. Hypercoagulable states as an evolving risk for spontaneous venous and arterial thrombosis. J Am Coll Surg 1994- 178(3):266−270.
- Licciardelo J, Moake J, Rudy C, et al. Elevated plasma von Willebrand factor levels and arterial occlusive complication associated with cisplatin-based treatment. Oncology 1985−42:296−300.
- Lindahl AK, Sandset PM, Abildgaard U. Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. Haemos'".sis 1990−20:253−262.
- Lowe GDO. Blood rheology in venous thrombosis. Clin Hemorheol 1984−4:571−573.
- Luzzato G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990- 17:147.
- Martin HP, Rohan JK et al. Newly diagnosed malignancy with venous thromboembolism. Search or wait and see? Thromb Haemost 1997−78(1):121−25.
- Matsumura Y, Kimura M, Yamamoto T, et al. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res 1988−79:13−27.
- Mehta P. Potential role of platelets in the pathogenesis of tumor metastasis. Blood 1984−63:55−63.
- Melnyk A, Theriault R, Andreeff M, Sansores Garcia L. Factor V Leiden and the risk of thrombosis in patients with solid tumors: a prospective case control study. Blood Suppl 1996−88:176.
- Menczer J, Schejter E, Geva D, et al. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factor and with survival. Eur J Gynec Oncol 1998- 19:82.
- Miller B, Heilmann L. Hemorheological parameters in patients with gynecological malignancies. Gynecol Oncol 1989 May-33(2): 177−81.
- Mirshahi SS, Pupde-Lauraine E, Sossia C, et al. D-dimer and Ca 125 levels in patients with ovarian cancer during antineoplastic therapy. Cancer 1992−69:2289.
- Monreal M, Roncales FJ, Ruiz J, et al. Secondary prevention of venous thromboembolism: a role for low-molecular-weight heparin. Haemostasis 1998 Sep-Oct-28(5):236−43.
- Moradi MM, Carson LF, et al. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor alpha in patients with ovarian epithelial cancer. Cancer 1993−72:2433.
- Morgan D, Edwards RL, Rickles FR. Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients. Flaemostasis 1988−18:158−163.
- Mueller-Berghaus G. Physiologie des Haemostasesystems. In: Transfusionsmedizin Berlin, Heidelberg, New York: Springer, 1996:45
- Mussoni L, Conforti G, Gambacorti-Passerini C, et al. Procoagulant and Fibrinolitic activity of human ovarian carcinoma cells in culture. Eur J Cancer Clin Oncol 1986−22(4):373−80.
- Nachman RL, Silverstein R. Flypercoagulable states. Ann Intern Med 1993- 119(8):819−827.
- Nand S, Fisher SG, Salgia R, Fisher RI. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complication. J Clin Oncol 1987−5:1998−2003.
- Nancl S, Messmore H. Hemostasis in malignancy. Am J Hematol 1990−35:45−55.
- Nathan FE, Hernandez E, Dunton CJ, Treat J, Switalska HI, et al. Plasma thrombospondin levels in patients with gynecological malignancies. Cancer 1994 Jun 1 -73(11):2853−8.
- Newland JR, Haire WD. Elevated plasminogen activator inhibitor levels found in patients with malignant conditions. Am J Clin Pathol 1991 -96:602.
- Nicholson GL, Custead SE. Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular integrity. Cancer Res 1985−45:331−336
- Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumo- cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992−52:3267−3272.
- Nierodzik ML, Plotkin A, Kajumoto F. Thrombin stimulates tumor-platelet adhesion in vitro anu metastasis in vivo. J Clin Invest 1991−87:229−236.
- Nordstrom M, Linblad B, et al. Deep vein thrombosis and occult malignancy: an epidemiological study. BMJ 1994−308:891−894.1650. Ratnoff. Hemostatic emergencies in malignancy. Semin Oncol 1989- 16:561 571.
- Pasquini E, Gianni L, Aitini E, et al. Acute disseminated intravascular coagulation syndrome in cancer patients. Oncology 1995−52(6):505−8.
- Peuscher FW, Cleton FJ. Significance of plasma fibrinopeptide A in patients with malignancy. J Clin Lab Med 1991−96:5−14
- Peuscher FW. Thrombosis and bleeding in cancer patients. Neth J Med 1981−24:23−35.
- Pinedo HM, Vcrheul FIM, D’Amato RJ, Folkman J. Involvement of platelet in tumor angiogenesis? Lancet 1998 Nov 28−352(9142): 1775−7.
- Pogliani EM, Fowst C, Maffe P, et al. CNS metastasis in ovarian cancer with microangiopathic hemolytic anemia associated with diffuse intravascular coagulation. Tumori 1988−74(6):731−6.
- Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost 1997−78(1): 141 -44.
- Prandoni P, Piccioli A. Venous thromboembolism and cancer: a two-way clinical association. Front Biosci 1997 Apr 1- 1:12−20.
- Prins MH, Lensing AWA, Hirsh J. Idiopathic deep vein thrombosis. Is search for malignant disease justified? Arch Intern Med 1994−154:1310−1312.
- Pujade-Lauraine E, Lu H, et al. The plasminogen activation system in ovarian tumors. Int J Cancer 1993−55:27
- Rambaldi A, Alessio G, et al. Induction of monocyte-macrophage procoagulant activity by transformed cell lines. J Immunol 1986−136:3848−3855
- Rampling MW, Whittingstall MW. The effects of fibrinogen and its plasmin degradation products on the rheology of erythrocyte suspension. Clin Hemorheol 1984−4:533
- Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992−11:249−266.
- Rella C, Coviello M, De Frenza N, et al. Plasma D-dimer measurement as a marker of gynecological tumors: comparison with CA. Tumori 1993−79:347−351.
- Rella C, Coviello M, et al. A prethrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 1996−40:151.
- Rickles FR, Hair GA, Zeff RA, et al. Tissue factor expression in human leucocytes and tumor cells. Thromb Haemost 1995−74:391−395.
- Rickles FR, Levine MN, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992 Nov-l 1 (3−4):237−48.
- Rickles FR, Levine MN. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998−28:43−49.
- Rocha F, Paramo JA, Fesenandez FJ, et al. Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 1989−54:699−707.
- Rosen PJ. Bleeding problems in the cancer patient. Flematol Oncol Clin North Am 1992−6:1315−1328.
- Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastsis. Curr Opin Hematol 1996 Sep-3(5):379−84.
- Ruffati A, Aversa S, Del Ross T, et al. Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome? Rheumatol 1994−21(11):2162−2163.
- Saeger W, Genzkow M. Venous thromboses and pulmonary embolisms in postmortem scries: probable causes by correlation of clinical data and basis diseases. Pathol Res ract 1994- 190:394.
- Sass PM. The involvement of selectins in cell adhesion, tumor progression and metastasis. Cancer Invest 1998−16:329−344.
- Sawaguchi K, Narumiya H, Yabushita H, et al. Relation between blood coagulability and prognosis in patients with ovarian cancer. Nippon Sanka Fujinka Gakkai Zasshi 1990−42(4):313−9.
- Saito K, Nagashima M, Iwata M, et al. The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors. Thromb Res 1990−58:355.
- Sawaguchi K, Higuchi M, Yabushita H. Effect of remission induction chemotherapy on blood coagulability in patients with gynecological malignancies. Nippon Gan Chiryo Gaccai Shi 1989−24(4):798−808.
- Schmalfeldt B, Kuhn W, Reuning U, et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptors and
- Schrock R, Hafter R, Schmidt L, et al. Tumor-associated antigens and fibrin derivates as
- Schwartz JD, Simantov R. Thrombosis and malignancy: pathogenesis and prevention. In Vivo 1998 Nov-Dec-12(6):619−24.
- Semeraro N, Montemurro P, Conese M, et al. Procoagulant activity of mononuclear phagocytes from different anatomical sites with gynecologic malignancies. Int J Cancer 1990−45:251.
- Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997−78:759−764.
- Senger D, van De Water L, Brown L, et al. Vascular permeability factor VPF, VEGF in tumor tumor biology. Cancer Metastasis Rev 1993−12:303−324.
- Shaler Al. The hypecoagulable states. Ann Intern Med 1985−102:814−828.
- Shoji M, Abe K, Nawroth PP, Rickles FR. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardivasc Med 1997−7:52−59.
- Shoji M, Hancock WW, Abe K. Activation of coagulation and angiogenesis in cancer: Iminunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998- 152:399 411.
- Siragusa S, Cosmi B, et al. Low-molecular-heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996 Mar-100(3):269−77.
- Sloand EM, Kenney DM, Chao FC. Platelet anti-thrombin defect in malignancy: platelet protein alterations. Blood 1987−69:479−485.
- Smorenburg SM, van Noorden CJ. The complex effects of heparins on cancer progression and metstasis in experimental studies. Pharmacol Rev 2001 Mar-53(l):93−106.
- Sporn JR, Rickles FR. Coagulation abnormalities in cancer patients. Clinical relevance. Chest 1994- 105:1639.
- Steingart RF1. Coagulation disorders associated with neoplastic disease. Recent Resulats Cancer Res 1988−108:37−43.
- Sundstrom H, Yltkorcala O, Kaupilla A. Serun selenium and thromboxane in patients with gynecological cancer. Carcinogenesis 1986−7(7): 1051 -2.
- Takeya FI, Tanaka Y, Suzuki K. Thrombosis and apoptosis. Rinsho Byori 1997−45(7):614−620.
- Tempfer C, Obermair A, Flefler L. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998−92:360−363.
- Thornes RD. Oral anticoagulant therapy of human cancer. J Med 1984−5:83−91.
- Tripodi A, Manucci PM. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem 1996−42:664−669.
- Uchiyama T, Matsumoto M, et al. Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy. Thromb Res 1990−59:955−965.
- Valente M, Ponte E. Thrombosis and cancer. Minerva Cardioangiol 2000 Apr-May-48(4−5):117−27.
- Valentine KA, Hull RD, Pineo GF. Low-molecular-weight heparin and mortality. Semin Thromb Hemost 1997−23(2):173−8.
- Vassalo RR, Kieber-Emmonson T et al. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 1992−27:6081−6085.
- Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau’s syndrome. Cancer 1997 Aug 15−80(4):649−55.
- Wersch van JWJ, Peters C, Ubachs JMH. Haemostasis in benign and malignant gynecological tumors: a pilot study. Eur J Clin Chem Biochem 1995−33:225.
- Yoda Y, Abe T. Fibrinopeptide A level and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 1981 -46:706 709.
- Zacharski LR, Howell AL, Memoli VA. The coagulation biology of cancer. Fibrinolysis 1992- 6 (Suppl l):39−42.
- Zacharski LR, Ornstein DL, Mamourian AC. Low molecular weight heparin and cancer. Semin Thromb Haem 2000−26, suppl. 1:69−77
- Zacharski LR, Wojtukiewicz MZ, Constantini V, et al. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992−18(1): 104−116.
- Zacharski LR, Memoli Va, Orstein Dl, et al. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Ca Inst 1993−85:1225.
- Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost 1998−80:10−23.
- Zeimet AG, Marth C, Dapunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994−170:549−554.
- Zhang Y, Deng Y, Luther T. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994−94:1320.
- Zuckerman E, Toubi E, Golan TD. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer 1995- 72:447.